Eisai

News

ASCO22: New data backs BMS' investment in Eisai's first canc...

Eisai's first-ever attempt at developing an antibody-drug conjugate for cancer was rewarded with a $3.1 billion licensing deal from Bristol-Myers Squibb, and new data reported at ASCO has g

News

Exit Aduhelm, enter lecanemab. Biogen and Eisai have another...

Here we go again.

News

Idorsia is first to EU market with orexin insomnia drug

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and

News

Eisai hands off responsibility for Aduhelm to Biogen

Japanese pharma Eisai has backed away from its 50:50 profit-sharing arrangement with Biogen for troubled Alzheimer's therapy Aduhelm, handing over full responsibility to its US counterpart.

News

Pharma group seeks digital measure standards for Alzheimer's

A group of pharma companies and academic groups have joined forces with the Digital Medicine Society (DiMe) to develop standardised, digital clinical measures that can be used in the develo

News

Concept of memory loss and brain aging due to dementia and alzheimer's disease as a medical icon with fall trees shaped as a human head losing leaves with 3D illustration elements.

Roche starts new four-year trial of Alzheimer's drug gantene...

With prospects of an early, accelerated approval for Roche's Alzheimer's disease candidate gantenerumab looking diminished, the drugmaker has launched a new four-year trial in the hope of b

ASCO22: New data backs BMS' investment in Eisai's first canc...

Exit Aduhelm, enter lecanemab. Biogen and Eisai have another...

Idorsia is first to EU market with orexin insomnia drug

Eisai hands off responsibility for Aduhelm to Biogen

Pharma group seeks digital measure standards for Alzheimer's

Roche starts new four-year trial of Alzheimer's drug gantene...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Eisai

Editor's Picks